CA-BE-MY-EYES
14.3.2023 18:04:39 CET | Business Wire | Press release
Be My Eyes, the mobile app that allows anyone to assist visually impaired people through live video calls, today announced Virtual Volunteer™, the first-ever digital visual assistant powered by OpenAI’s new GPT-4 language model.
The new tool from Be My Eyes integrates OpenAI’s latest generative AI technology, with the goal of providing an unprecedented level of accessibility and power to the 253 million people who are blind or have low vision globally.
“We are entering the next wave of innovation for accessibility technology powered by AI. This new Be My Eyes feature will be transformative in providing people who are blind or have low vision with powerful tools to better navigate physical environments, address everyday needs, and gain more independence,” said Mike Buckley, CEO of Be My Eyes. “We are thrilled to work with OpenAI to further our mission of improving accessibility for the 253 million people who are blind or have low-vision, with safe and accessible applications of generative AI.”
The Virtual Volunteer feature will be integrated into the existing app and contains a dynamic new image-to-text generator powered by GPT-4. Users can send images via the app to an AI-powered Virtual Volunteer, which will answer any question about that image and provide instantaneous, conversational visual assistance for a wide variety of tasks.
What sets the Virtual Volunteer tool apart from other image-to-text technology available today is the context it provides, with highly nuanced explanations and conversational abilities not yet seen in the digital assistant field. For example, if a user sends a picture of the inside of their refrigerator, the Virtual Volunteer will not only be able to correctly identify the items within, but also extrapolate and analyze what can be prepared with those ingredients. The tool can also then offer a number of recipes for those ingredients and send a step-by-step guide to prepare them.
This new feature promises to not only better support the blind and low-vision community through the Be My Eyes app, but it will also offer a way for businesses to better serve their customers by prioritizing accessibility. Be My Eyes plans to begin beta testing this with corporate customers in the coming weeks, and to make it broadly available later this year as part of the company’s Accessible CX™ offering.
Since its founding in 2015, Be My Eyes has worked to connect its 6.3 million volunteers to users to assist them with everyday tasks, and the company’s mission is to make the world more accessible for people who are blind or have low vision.
In the near future, Be My Eyes plans to apply this technology to provide people with powerful tools and capabilities to enrich their virtual assistant experience in complex ways – for example, navigating a train system in an unfamiliar place, traveling in a foreign country where translation support is needed, browsing websites and social media platforms, online shopping, and a host of other scenarios to be discovered in testing.
People who are blind or have low vision can register for the wait list in the iOS app. Just like the existing volunteer service, this tool is free for all blind and low-vision community members using the Be My Eyes app.
About Be My Eyes
Based in Denmark and launched in 2015, Be My Eyes is a global community that connects people who are blind or have low vision with sighted volunteers or company representatives. On the app, volunteers assist blind and low-vision users through a live video connection and work together to tackle challenges and handle a wide range of tasks. With the Specialized Help feature, blind and low-vision users can connect with company representatives for accessible customer support. The app harnesses the power of generosity, technology, and human connection so that people who are blind or have low vision can lead more independent lives. Be My Eyes is accessible in more than 150 countries worldwide and in over 180 languages. The app is free and available for both iOS and Android. Learn more at bemyeyes.com and join us on LinkedIn, Twitter, Facebook, Instagram, and TikTok.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom